SOURCE: Kalorama Information

Kalorama Information

July 13, 2011 12:37 ET

Orthopedic Device Makers Seek to Boost Profits With Biomaterial Products

NEW YORK, NY--(Marketwire - Jul 13, 2011) - Advances in gene therapy and stem cell research are driving the market for orthopedic biomaterials, notes Kalorama Information in its recently published report, "Orthopedic Biomaterials, the World Market." According to the healthcare market research firm, the orthopedic biomaterials market represents 14% of the global orthopedics market, or about $5.8 billion in 2010, with double digit annual growth expected through 2016.

Musculoskeletal conditions are the most common cause of chronic disability. These conditions comprise over 150 diseases and syndromes, which are usually progressive and associated with pain. They can broadly be categorized as joint diseases, physical disabilities, spinal disorders, and conditions resulting from trauma. Those conditions with the greatest impact on society include rheumatoid arthritis, osteoarthritis, osteoporosis, lower back pain, and limb trauma. Approximately 2 million bone-grafting procedures in the spine, extremities and pelvis are performed each year on a worldwide basis.

"Advances in gene therapy and stem cell research may offer new solutions for state-of-the-art treatments for these musculoskeletal conditions," notes Bruce Carlson, publisher of Kalorama Information. "Many researchers believe that genetically engineered stem cells will have a significant impact on the fields of regenerative medicine and tissue engineering as a powerful cell source that will work, in conjunction with biomaterials, to treat tissue and bone loss."

Two areas in biomaterials that have gained significant momentum in recent years are growth factor-based and cell-based bone graft substitutes. Growth factor-based recombinant bone morphogenetic proteins (BMPs) include recombinant human bone morphogenetic protein 2 (BMP-2) and recombinant human osteogenic protein-1 (BMP-7), which are used as autologous bone graft substitutes. Cell-based bone substitutes are considered by some to be the wave of the future and include Mesenchymal stem cells. These are involved in osteogenic differentiation of cells at the site of bone generation and used in the allograft bone substitutes currently on the market.

"As standard orthopedics gets more competitive, biomaterials have become an area of interest for companies like Stryker, J&J, Wright and Zimmer," notes Carlson.

Kalorama Information's "Orthopedic Biomaterials, the World Market" looks at the products and markets for bone allografts and bone graft substitutes, which include allograft bone substitutes, ceramic-based, polymer-based, factor-based (recombinant growth factors) and hyaluronic acid synovial fluid substitutes. Coverage includes historical revenues from 2006-2010, forecasts to 2016, competitive market share, a discussion of issues and trends, a review of new products, and profiles of key companies in the field.

About Kalorama Information

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter and LinkedIn.

Contact Information